LUPIN2024-07-012024-09-30 LUPIN2024-07-012024-09-30 LUPIN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member LUPIN2024-07-012024-09-30in-bse-fin:OneOperatingExpenses02Member LUPIN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member LUPIN2024-07-012024-09-30in-bse-fin:FourOperatingExpenses02Member LUPIN2024-09-30 LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue01Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue02Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue03Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentRevenue04Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue01Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue02Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue03Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentRevenue04Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults01Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults02Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults03Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentResults04Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults01Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults02Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults03Member LUPIN2024-07-012024-09-30in-bse-fin:FourReportableSegmentResults04Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets01Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets02Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets03Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentAssets04Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member LUPIN2024-09-30in-bse-fin:OneReportableSegmentLiabilities01Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member LUPIN2024-09-30in-bse-fin:OneReportableSegmentLiabilities02Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member LUPIN2024-09-30in-bse-fin:OneReportableSegmentLiabilities03Member LUPIN2024-07-012024-09-30in-bse-fin:OneReportableSegmentLiabilities04Member LUPIN2024-09-30in-bse-fin:OneReportableSegmentLiabilities04Member LUPIN2024-07-012024-09-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LUPIN2024-07-012024-09-30in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member LUPIN2024-07-012024-09-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member LUPIN2024-07-012024-09-30in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500257 LUPIN NOTLISTED Lupin Limited Equity 2024-04-01 2025-03-31 2024-11-07 2024-10-22 INR Millions Half yearly 14:45:00 18:15:00 2024-11-07 2024-11-07 true Cash Flow Indirect Not applicable Multi segment 2024-07-01 2024-09-30 Unaudited Consolidated 56727300000.00 422900000.00 57150200000.00 11181200000.00 6599800000.00 -881600000.00 10075200000.00 708700000.00 2569200000.00 16349100000.00 46601600000.00 10548600000.00 0.00 10548600000.00 2029300000.00 -75500000.00 1953800000.00 0.00 8594800000.00 0.00 0.00 0.00 0.00 8594800000.00 576900000.00 9171700000.00 8526300000.00 68500000.00 9066400000.00 105300000.00 912300000.00 2 18.70 18.64 0.00 0.00 18.70 18.64 0.00 0.00 0.00 1. The above Consolidated Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 07, 2024. The Statutory Auditors of the Company have carried out limited review of the above Consolidated Financial Results pursuant to Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. 2. The Consolidated Financial Results include the financial results of the subsidiaries, Lupin Pharmaceuticals, Inc. - U.S.A., Lupin Australia Pty Limited - Australia, Nanomi B.V. - Netherlands, Pharma Dynamics (Proprietary) Limited - South Africa, Hormosan Pharma GmbH - Germany, Multicare Pharmaceuticals Philippines Inc. - Philippines, Lupin Atlantis Holdings SA - Switzerland, Lupin Healthcare (UK) Limited - U.K., Lupin Pharma Canada Limited - Canada, Generic Health Pty Limited - Australia, Bellwether Pharma Pty Limited - Australia (upto June 11, 2023), Lupin Mexico S.A. de C.V. - Mexico, Lupin Philippines Inc. - Philippines, Lupin Diagnostics Limited - India, Generic Health SDN. BHD. - Malaysia, Lupin Inc. - U.S.A., Laboratorios Grin S.A. de C.V. - Mexico, Medquimica Industria Farmaceutica LTDA - Brazil, Novel Laboratories, Inc.- U.S.A., Lupin Research Inc. - U.S.A., Lupin Management Inc. - U.S.A, Lupin Europe GmbH - Germany, Lupin Biologics Limited - India, Lupin Oncology Inc. - U.S.A, Lupin Digital Health Limited - India, Avenue Coral Springs LLC - U.S.A., Southern Cross Pharma Pty Ltd - Australia, Lupin Life Sciences Limited - India (w.e.f. July 17, 2023) (formerly known as Lupin Atharva Ability Limited - India), Lupin Manufacturing Solutions Limited - India (w.e.f. July 24, 2023), Medisol S.A.S. - France (w.e.f. September 01, 2023), Lymed S.A.S. - France (w.e.f. September 01, 2023 till July 08, 2024), Lupin Lanka (Private) Ltd. - Sri Lanka (w.e.f. August 05, 2024), Lupin NZ Ltd. - New Zealand (w.e.f. August 08, 2024) and a Trust, Lupin Foundation - India and a joint venture, YL Biologics Limited - Japan. 3. The Consolidated Financial Statements are prepared in accordance with Ind AS 110 Consolidated Financial Statements and Ind AS 28 Investments in Associates and Joint Ventures . 4. During the quarter, 227,359 (year-to-date 464,404) equity shares of Rs. 2/- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans (ESOPs), resulting in an increase in the paid-up share capital by Rs. 0.4 million (year-to-date Rs. 0.9 million) and securities premium account by Rs. 366.6 million (year-to-date Rs. 640.0 million). 5. As approved by the Members of the Company at the 42nd Annual General Meeting held on August 02, 2024, the Company has disbursed on August 07, 2024 a final dividend of Rs. 8/- per equity share of the face value of Rs. 2/- each aggregating Rs. 3,647.7 million. 6. During the current quarter and six months ended September 30, 2024, the Group has made provision of Rs. 585.1 million towards ongoing dispute. 7. During the previous quarter ended June 30, 2024 and six months ended September 30, 2024, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of USD 9.0 million (Rs. 750.5 million) in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. 8. During the previous six months ended September 30, 2023 and year ended March 31, 2024, Sales / Income from operations includes milestone income of Rs. 2,052.5 million (USD 25.0 million) from AbbVie for successful achievement of key milestone for its Phase 1 clinical stage MALT1 inhibitor program. 9. During the year ended March 31, 2024, the Group had recognised an impairment charge of Rs. 2,012.5 milion related to intangibles assets (including discontinued ANDAs) and certain tangible assets. Multi segment 2024-04-01 2024-09-30 Unaudited Consolidated 112730600000.00 855300000.00 113585900000.00 22638600000.00 13005400000.00 -1299000000.00 19785600000.00 1388800000.00 5046300000.00 32541300000.00 93107000000.00 20478900000.00 0.00 20478900000.00 4404800000.00 -576100000.00 3828700000.00 0.00 16650200000.00 0.00 0.00 0.00 0.00 16650200000.00 50300000.00 16700500000.00 16539400000.00 110800000.00 16587400000.00 113100000.00 912300000.00 2 36.28 36.16 0.00 0.00 36.28 36.16 0.00 0.00 0.00 Net (gain)/ loss on foreign currency transactions -320800000.00 Other Expenses 16669900000.00 Net (gain)/ loss on foreign currency transactions 133100000.00 Other Expenses 32408200000.00 778600000.00 48157600000.00 6349900000.00 0.00 23061900000.00 17755500000.00 1647200000.00 0.00 286100000.00 483700000.00 0.00 33400000.00 727400000.00 1244500000.00 3476100000.00 2639700000.00 104618500000.00 52847400000.00 14984300000.00 51112500000.00 11094600000.00 3044200000.00 77300000.00 6286900000.00 86599800000.00 386800000.00 10367100000.00 150201100000.00 0.00 0.00 254819600000.00 912300000.00 155506000000.00 156418300000.00 157196900000.00 5586700000.00 0.00 3611800000.00 9198500000.00 4098700000.00 2400600000.00 0.00 2028400000.00 17726200000.00 26133400000.00 29545600000.00 7456100000.00 63135100000.00 10339600000.00 1203400000.00 5218400000.00 0.00 79896500000.00 0.00 0.00 97622700000.00 254819600000.00 1) Property, Plant and Equipment includes Right-of-use Assets of Rs. 3,332.9 mn. 2) Other Non-current Assets includes Non-current tax assets of Rs. 629.8 mn. 3) Other Non-current financial liabilities includes Lease liabilities of Rs. 1801.1 mn. 4) Trade payables includes Total outstanding dues of Micro Enterprises and Small Enterprises of Rs. 785.4 mn. and Total outstanding dues of other than Micro Enterprises and Small Enterprises of Rs. 28,760.2 mn. 5) Other Current Financial Liabilities includes lease liabilities of Rs. 903.8 mn. Less: Inter segment Assets 0.00 Less: Inter segment Liabilities 0.00 Others 262400000.00 Pharmaceuticals 56472000000.00 Less: Inter segment Assets 0.00 Less: Inter segment Liabilities 0.00 Others 476200000.00 Pharmaceuticals 112261500000.00 56734400000.00 112737700000.00 7100000.00 7100000.00 56727300000.00 112730600000.00 Less: Inter segment Assets 0.00 Less: Inter segment Liabilities 0.00 Others -341500000.00 Pharmaceuticals 10890100000.00 Less: Inter segment Assets 0.00 Less: Inter segment Liabilities 0.00 Others -722500000.00 Pharmaceuticals 21201400000.00 10548600000.00 20478900000.00 10548600000.00 20478900000.00 Less: Inter segment Assets -3022200000.00 Less: Inter segment Liabilities 0.00 Others 2445500000.00 Pharmaceuticals 255396300000.00 254819600000.00 Less: Inter segment Assets 0.00 Less: Inter segment Liabilities -2971200000.00 Others 3814000000.00 Pharmaceuticals 96779900000.00 97622700000.00 1388800000.00 -3040800000.00 -3472500000.00 0.00 399000000.00 -660000000.00 87200000.00 78700000.00 -760500000.00 -261700000.00 0.00 -1148000000.00 124100000.00 5046300000.00 0.00 -4052100000.00 50100000.00 -189100000.00 327200000.00 -189700000.00 0.00 493100000.00 230500000.00 -24400000.00 0.00 -171800000.00 0.00 235700000.00 0.00 -6496100000.00 13982800000.00 0.00 0.00 0.00 3002400000.00 0.00 10980400000.00 0.00 562600000.00 0.00 0.00 0.00 0.00 0.00 0.00 26700000.00 4682000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 484200000.00 0.00 -4748010000.00 0.00 -9481710000.00 0.00 0.00 0.00 0.00 0.00 0.00 345100000.00 0.00 5165600000.00 0.00 0.00 594100000.00 3653200000.00 1255200000.00 0.00 0.00 8200000.00 1506890000.00 0.00 1506890000.00 9832800000.00 11339690000.00 Items that will not be reclassified subsequently to profit or loss -110900000.00 Items that will not be reclassified subsequently to profit or loss -215600000.00 -110900000.00 -215600000.00 -38800000.00 -75400000.00 Items that will be reclassified subsequently to profit or loss 649000000.00 Items that will be reclassified subsequently to profit or loss 286000000.00 649000000.00 286000000.00 0.00 95500000.00